There are clinical trial data indicating that anti-IL23p19 subunit mAb treatment met the primary endpoints and is effective in psoriatic arthritis (PsA) patients [11] but not in rheumatoid arthritis (RA) patients [12]. Here, IL23A is linked to rheumatoid arthritis.